Skip to main content
TipRanks
Go Ultimate75% OFF

Larimar Therapeutics (LRMR) Stock Statistics & Valuation Metrics

1,155 Followers

Total Valuation

Larimar Therapeutics has a market cap or net worth of $313.73M. The enterprise value is $167.06M.

Market Cap
$313.73M
Enterprise Value
$167.06M

Share Statistics

Larimar Therapeutics has 103,882,935 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
103,882,935
Owned by Insiders
36.17%
Owned by Institutions
34.06%

Financial Efficiency

Larimar Therapeutics’s return on equity (ROE) is -2.12 and return on invested capital (ROIC) is -209.97%.

Return on Equity (ROE)
-2.12
Return on Assets (ROA)
-1.14
Return on Invested Capital (ROIC)
-209.97%
Return on Capital Employed (ROCE)
-2.13
Revenue Per Employee
0
Profits Per Employee
-2.33M
Employee Count
71
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Larimar Therapeutics is -1.52. Larimar Therapeutics’s PEG ratio is 0.05.

PE Ratio
-1.52
PS Ratio
0.00
PB Ratio
2.46
Price to FCF
-2.01
Price to Operating Cash Flow
-2.01
PEG Ratio
0.05

Income Statement

In the last 12 months, Larimar Therapeutics had revenue of 0 and earned -165.67M in profits. Earnings per share was -2.27.

Revenue
0
Gross Profit
0
Operating Income
-172.50M
Pretax Income
-165.67M
Net Income
-165.67M
EBITDA
-165.32M
Earnings Per Share (EPS)
-2.27

Cash Flow

In the last 12 months, operating cash flow was -155.92M and capital expenditures -153,000, giving a free cash flow of -156.08M billion.

Operating Cash Flow
-155.92M
Free Cash Flow
-156.08M
Free Cash Flow per Share
-1.50

Dividends & Yields

Larimar Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-49.75%
Earnings Yield
-55.02%

Stock Price Statistics

Beta
1.92
52-Week Price Change
-8.21%
50-Day Moving Average
2.95
200-Day Moving Average
3.77
Relative Strength Index (RSI)
59.54
Average Volume (3m)
1.33M

Important Dates

Larimar Therapeutics upcoming earnings date is Mar 19, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 05, 2026
Next Earnings Date
Mar 19, 2027
Ex-Dividend Date
―

Financial Position

Larimar Therapeutics as a current ratio of 2.19, with Debt / Equity ratio of 5.21%

Current Ratio
2.19
Quick Ratio
2.19
Debt to Market Cap
0.00
Net Debt to EBITDA
0.49
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, Larimar Therapeutics has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Larimar Therapeutics EV to EBITDA ratio is -1.31, with an EV/FCF ratio of -1.45.

EV to Sales
0.00
EV to EBITDA
-1.31
EV to Free Cash Flow
-1.45
EV to Operating Cash Flow
-1.45

Balance Sheet

Larimar Therapeutics has $156.27M in cash and marketable securities with $4.96M in debt, giving a net cash position of $151.31M billion.

Cash & Marketable Securities
$156.27M
Total Debt
$4.96M
Net Cash
$151.31M
Net Cash Per Share
$1.46
Tangible Book Value Per Share
$1.23

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin
0.00%
Operating Margin
0.00%
Pretax Margin
0.00%
Net Profit Margin
0.00%
EBITDA Margin
0.00%
EBIT Margin
0.00%

Analyst Forecast

The average price target for Larimar Therapeutics is $16.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target
$16.00
Price Target Upside
429.80% Upside
Analyst Consensus
Strong Buy
Analyst Count
4
Revenue Growth Forecast
―
EPS Growth Forecast
-27.00%

Scores

Smart Score
9
AI Score
50